Kyowa Hakko Kogyo Co., Ltd.

Other

Kyowa Hakko Kirin Co., Limited

Kenya Shitara

Shiro Akinaga

Toshihiko Ishii

Yuka Sasaki

Junji Kanazawa

So Ohta

Rinpei Niwa

Chikara Murakata

Yukimasa Shiotsu

Tamio Mizukami

Nobuyoshi Amishiro

Pui-Kai Li

Yoji Ino

Yutaka Kanda

Yutaka Saitoh

Masami Okabe

Shiro Soga

Yoshinori Yamashita

Keiko Ochiai

Tatsuya Tamaoki

Mitsunobu Hara

Tsutomu Agatsuma

Harumi Ogawa

Mayumi Miyata

Tadakazu Akiyama

Hiroyuki Ishida

Hirofumi Nakano

Makoto Morimoto

Eiji Kobayashi

Fumihiko Kanai

Shinji Nara

Taisuke Nakata

Takako Shiraki

Motoo Yamasaki

Yutaka Saito

Ken Kobayashi

Akira Asai

Katsuhiko Ando

Toshiyuki Suzawa

Yasushi Sakai

Isami Takahashi

Yasuki Kato

Ryuichiro Nakai

Takayuki Nakashima

Akira Mihara

Hiroko Kusano

Masahiro Yamauchi

Jun-ichi Saito

Kumiko Maruyama

Kazuhito Akasaka

Hiroshi Nakagawa

Jiro Kajita

Noboru Konishi

Tetsuo Yoshida

Takeshi Iwata

Takaaki Uochi

Junichi Watanabe

Jun Eishima

Takeshi Takahashi

Akira Sato

Mitsuru Takahashi

Koji Yamada

Masaji Kasai

Hiroshi Kase

Hiromitsu Saito

Tadashi Ashizawa

Tadashi Hirata

Hideharu Anazawa

Katsushige Gomi

Timothy A Grese

Shigeru Chiba

Kenichi Mochida

Takao Iida

Ikuo Matsukuma

Keiichi Takahashi

Mayumi Yoshida

Timothy S Powers

Youichi Uosaki

Douglas Linn Gernert

Hideki Kawasaki

Kozo Ouchi

Shigeo Katsumata

Yukiteru Mimura

Kinya Yamashita

Takashi Kuwabara

Yoko Kato

Masami Kaneko

Yushi Kitamura

Toru Sugaya

Yasushi Shida

Shingo Kakita

Toshimitsu Takiguchi

Yutaka Osawa

Atsuhiro Hasegawa

Yumiko Aotani

Rieko Nakatsu

Ritsuko Katahira

Rieko Tanaka

David A Johnson

A coated fine particle comprisisng: (i) a complex of a drug and a cationic lipid, wherein (a) the drug is a nucleic acid and the complex is obtained by mixing the drug and the cationic lipid in water, wherein the complex has a diameter of 10 nm to 1,000 nm, and (ii) a lipid layer formed of lipid(s), wherein the lipid(s) is selected from phospholipid, glyceroglycolipid, sphingoglycolipid, cholesterol and synthetic lipid, wherein the complex is coated with the lipid layer.

Fine particles coated with lipid membrane

A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.

Medicament comprising recombinant antibody against chemokine receptor CCR4

The present invention provides Hsp90 family protein inhibitors comprising, as an active ingredient, a benzoyl compound represented by general formula (I): (wherein n represents an integer of 0 to 10; Rrepresents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONRRor the like; Rrepresents substituted or unsubstituted aryl, a substituted or unsubstituted aromatic heterocyclic group or the like; Rand R, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl or the like; and Rand R, which may be the same or different, each represent a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like) or a prodrug thereof, or a pharmaceutically acceptable salt of said benzoyl compound or said prodrug.

Hsp90 family protein inhibitors

An object of the present invention is to provide a safe, convenient and efficient method for coating fine particles with lipid membrane. There is provided a method for coating fine particles with lipid membrane, characterized in that, the rate of a polar organic solvent in an aqueous solution containing the polar organic solvent where the fine particles are dispersed and lipid is dissolved, is decreased.

Method of coating fine particles with lipid film

The present invention relates to a chemically modified polypeptide in which at least one of hydroxyl groups in the polypeptide molecule is modified with a polyalkylene glycol derivative; a method for producing the modified polypeptide; a method of treatment using the modified polypeptide; use of the modified polypeptide; a pharmaceutical preparation comprising the modified polypeptide; and a composition for treatment comprising the modified polypeptide.

Chemically modified polypeptides

Provided is steroid sulfatase inhibitors comprising, as the active ingredient, an estra-1,3,5(10)-triene derivative which is represented by formula (I):{wherein Rand Rare the same or different and represent a hydrogen atom, a lower alkyl group or, etc.; Rrepresents a hydrogen atom etc.; Rrepresents a hydrogen atom etc.; Rrepresents a hydrogen atom etc.; Rrepresents a cyano group, an amino group, COR(wherein Rrepresents a substituted lower alkyl group etc.), a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, etc}, or pharmaceutically acceptable salts thereof.

Estra-1,3,5(10)-triene derivatives

This invention relates to substituted piperidine derivatives having at least one six-membered ring substituent. The piperidine derivatives exhibit antitumor activity and are useful as pharmaceuticals such as an antitumor agent.

Piperidine derivatives

Staurosporin derivatives

Estra-1,3,5(10),16-tetraene derivatives

Radicicol derivatives

The present invention provides a method of efficiently screening for steroid sulfatase activity-inhibiting compounds which are useful for the treatment of hormone-dependent diseases such as breast cancer, etc. by causing a test compound to act on cells carrying an introduced steroid sulfatase gene and estimating the inhibiting activity of the compound on the growth of the cells.

Method for searching steroid sulfatase inhibitors

2-piperidone compounds

Growing community of inventors

Shizuoka, Japan

Shiro Akinaga